



AstraZeneca Case Study

AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease in important areas of healthcare.

The Bristol site was established in 1970 as part of ICI Pharmaceuticals Division and transferred to Zeneca in 1993. The merger of Zeneca with Astra in 1999 formed AstraZeneca the fourth largest pharmaceutical company in the world. Work at the Bristol site incorporates manufacturing and research & development. The site manufactures active pharmaceutical ingredients that are used in cardiovascular and schizophrenia treatments across the world. Research and development looks for the most cost effective and environmentally sustainable ways to manufacture active components of medicines.

Backed by strong science and wide-ranging commercial skills, AstraZeneca is committed to sustainable development of business, the delivery of new medicines that make a difference in the lives of patients and create value for shareholders and wider society.

The 175acre site employs 350 people in chemical processing, engineering and scientific roles. Over the last ten years more than £130m has been invested including £25 million in a bio-treatment plant that uses the latest fungal/bacterial technology. Currently a further £17m up-grade to the production area is underway.

David Mitchell, the Site Manager commented, “Through this period of sustained investment in the site, we have benefited from the skilled population of people attracted to Bristol by the quality of life and the environment in this region. Those who have come and worked for us in both construction and the operation of our business have contributed to our success.”

www.astrazeneca.com
www.astrazeneca.co.uk

www.investinbristol.com

